Sequence: RKKRRQRRRHRRKKR
| Experiment Id | EXP001414 |
|---|---|
| Paper | Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silen |
| Peptide | dTAT (double TAT) |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | dTAT dose escalation up to 1000 mg/kg (tail vein); formulation stock 174 mg/mL dTAT then serial dilution |
| Rna Concentration | Very low siRNA to enable complex formation (final ~0–9.46 nM per 200 µL injection; not intended as therapeutic dose) |
| Mixing Ratio | dTAT + control siRNA + CaCl2 (0.3 M stock; final ~70 mM) + glucose (2%) |
| Formulation Format | Calcium-condensed CPP/siRNA nanoparticles (IV) |
| Formulation Components | dTAT + control siRNA + CaCl2 + glucose |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Balb/C mice (male; ~12 weeks) dose-escalation toxicity study |
| Administration Route | Intravenous (tail vein) |
| Output Type | Acute toxicity / behavior after IV dosing |
| Output Value | |
| Output Units | |
| Output Notes | Minimal toxicity observed up to 1000 mg/kg dTAT; highest dose caused transient behavioral phenotype with full recovery. |
| Toxicity Notes | Primary outcome of this arm; no lethal toxicity reported within tested range. |
| Curation Notes |